Padlan EA - Search Results

1

Engineering of antibodies for breast cancer therapy: construction of chimeric and humanized versions of the murine monoclonal antibody BrE-3.

Couto JR, Blank EW, Peterson JA, Kiwan R, Padlan EA, Ceriani RL. Couto JR, et al. Among authors: padlan ea. Adv Exp Med Biol. 1994;353:55-9. doi: 10.1007/978-1-4615-2443-4_7. Adv Exp Med Biol. 1994. PMID: 7985542 No abstract available.

2

Humanization of KC4G3, an anti-human carcinoma antibody.

Couto JR, Padlan EA, Blank EW, Peterson JA, Ceriani RL. Couto JR, et al. Among authors: padlan ea. Hybridoma. 1994 Jun;13(3):215-9. doi: 10.1089/hyb.1994.13.215. Hybridoma. 1994. PMID: 7927365

3

CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity.

Iwahashi M, Milenic DE, Padlan EA, Bei R, Schlom J, Kashmiri SV. Iwahashi M, et al. Among authors: padlan ea. Mol Immunol. 1999 Oct-Nov;36(15-16):1079-91. doi: 10.1016/s0161-5890(99)00094-2. Mol Immunol. 1999. PMID: 10698310

4

Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody.

De Pascalis R, Iwahashi M, Tamura M, Padlan EA, Gonzales NR, Santos AD, Giuliano M, Schuck P, Schlom J, Kashmiri SV. De Pascalis R, et al. Among authors: padlan ea. J Immunol. 2002 Sep 15;169(6):3076-84. doi: 10.4049/jimmunol.169.6.3076. J Immunol. 2002. PMID: 12218124

5

A T cell receptor V alpha domain expressed in bacteria: does it dimerize in solution?

Plaksin D, Chacko S, McPhie P, Bax A, Padlan EA, Margulies DH. Plaksin D, et al. Among authors: padlan ea. J Exp Med. 1996 Oct 1;184(4):1251-8. doi: 10.1084/jem.184.4.1251. J Exp Med. 1996. PMID: 8879196 Free PMC article.

6

X-ray crystallography of antibodies.

Padlan EA. Padlan EA. Adv Protein Chem. 1996;49:57-133. doi: 10.1016/s0065-3233(08)60488-x. Adv Protein Chem. 1996. PMID: 8908297 Review. No abstract available.

7

Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49.

Kashmiri SV, Iwahashi M, Tamura M, Padlan EA, Milenic DE, Schlom J. Kashmiri SV, et al. Among authors: padlan ea. Crit Rev Oncol Hematol. 2001 Apr;38(1):3-16. doi: 10.1016/s1040-8428(00)00133-5. Crit Rev Oncol Hematol. 2001. PMID: 11255077 Review.

8

Rapid humanization of the Fv of monoclonal antibody B3 by using framework exchange of the recombinant immunotoxin B3(Fv)-PE38.

Benhar I, Padlan EA, Jung SH, Lee B, Pastan I. Benhar I, et al. Among authors: padlan ea. Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12051-5. doi: 10.1073/pnas.91.25.12051. Proc Natl Acad Sci U S A. 1994. PMID: 7991583 Free PMC article.

9

Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues.

Gonzales NR, Padlan EA, De Pascalis R, Schuck P, Schlom J, Kashmiri SV. Gonzales NR, et al. Among authors: padlan ea. Mol Immunol. 2003 Oct;40(6):337-49. doi: 10.1016/s0161-5890(03)00166-4. Mol Immunol. 2003. PMID: 14522015

10

Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49.

Kashmiri SV, Shu L, Padlan EA, Milenic DE, Schlom J, Hand PH. Kashmiri SV, et al. Among authors: padlan ea. Hybridoma. 1995 Oct;14(5):461-73. doi: 10.1089/hyb.1995.14.461. Hybridoma. 1995. PMID: 8575795

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

118 results

Search Page

Filters